Markets
Plug Power
(Will Waldron/Getty Images)
Incentives!

Plug Power soars on tax-incentive news

Guidance on a lucrative tax incentive created by the Biden administration’s Inflation Reduction Act sent Plug Power soaring on Monday.

Matt Phillips

Shares of Plug Power rocketed higher on Monday after analysts at JPMorgan said the company stood to benefit from recent guidance from the Treasury Department about a lucrative hydrogen-related tax credit.

Essentially, the idea is that the final federal-government guidance on how these tax breaks — known as 45V — can be used might boost investment in cleaner ways to produce hydrogen, which could help in meeting climate-change goals.

Currently, hydrogen is primarily harvested from natural gas in a process that produces large carbon-dioxide emissions. (It’s possible to produce it without such emissions, but it’s expensive, which is why government incentives are required.)

Plug Power makes a piece of equipment called electrolyzers that split water into hydrogen and oxygen and are important parts of clean hydrogen production.

In a note published on Monday, JPMorgan analysts said that additional US hydrogen investment could boost domestic sales of Plug Power’s electrolyzers, most of which are sold in Europe and Australia.

Positive 45V guidance revisions will primarily help the electrolyzer side of the business, though upside has not been baked into the 2025 revenue guidance; rather revenue growth will be driven by what is already in the backlog and international opportunities, with only a few hundreds of MWs of 2025 electrolyzer deals linked specifically to the US.

JPMorgan analysts also included a word of caution, adding that “while the final guidance being released is certainly positive in our view, we think some investors may still harbor concerns around the implementation of the credit which will largely fall to the incoming Trump administration.”

If there are concerns, it’s hard to find them in the stock market today, as the stock is up more than 20%.

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.